The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland
Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS f...
Gespeichert in:
| Veröffentlicht in: | BMC clinical pharmacology 2010-10, Vol.10 (1), p.15-15, Article 15 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 15 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | BMC clinical pharmacology |
| container_volume | 10 |
| creator | Timonen, Johanna Bengtström, Marina Karttunen, Pekka Ahonen, Riitta |
| description | Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical companies' perspective was explored with a focus on the number of employees, the range of sales packages on the market, the marketing activities, the research and development of new pharmaceutical products and storage of pharmaceuticals.
A cross-sectional postal survey was conducted among pharmaceutical companies with an office in Finland and substitutable medicines in the Finnish pharmaceutical market one year (2004) and five years (2008) after the introduction of GS. Completed questionnaires were returned by 16 original and 7 generic product companies in 2004 (response rate 56%, n = 41) and by 16 original and 6 generic product companies in 2008 (response rate 56%, n = 39). Descriptive statistical analyses were performed.
The number of employees (2004: n = 6/16, 2008: n = 7/16) and the amount of prescription medicine marketing (2004: n = 7/16, 2008: n = 8/16) decreased in many of the original product companies after the introduction of GS. GS resulted in problems related to the storage of pharmaceuticals in the original product companies shortly after GS was introduced (p = 0.032 between 2004 and 2008). In the generic product companies, the prescription medicine representatives' visits to pharmacies increased at the beginning of GS (p = 0.021 between 2004 and 2008). In addition, GS caused problems with the storage of pharmaceuticals one year and five years after the reform (2004: n = 4/7, 2008: n = 3/6). The differences between original and generic product companies regarding the impacts of GS were not, however, statistically significant. GS did not affect on the range of sales packages on the market or the research activities of the majority of companies.
The study suggests that GS has had impacts on the activities of pharmaceutical companies in Finland. There were also some differences, although not statistically significant, between the surveyed original and generic product companies regarding the self-reported impacts of GS. More investigations are needed in this field. |
| doi_str_mv | 10.1186/1472-6904-10-15 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2974660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A241385979</galeid><sourcerecordid>A241385979</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4605-2150f1c522ba065fcd4b022f3d002e1693f57991c13dafa14941826276cb51713</originalsourceid><addsrcrecordid>eNp1Uk1r3DAQNaWlSdOeeyuiPeTkRCPb8upSSEO_INBLehayPNpVsC1XshfyI_OfOs6mS7Yk2GB75r3n92aUZe-BnwGs5DmUtcil4mUOPIfqRXa8r7x89H6UvUnphnOoV1C8zo4EV7JcSXWc3V1vkPl-NHZiwbE1Dhi9ZWlu0uSnefJhYHRPhCKI3_rJY1qQ48bE3lgkiDUds4E0hqWXM0P0uMVb5mLo76n77ikbMaYRFykkYWS3aCIzQ8vcUlm-EjNuwnhP9MMUQzvbnY9n_PmByENHIm-zV850Cd89PE-y39--Xl_-yK9-ff95eXGVN6XkVS6g4g5sJURjuKycbcuGC-GKlnOBIFXhqlopsFC0xhkoVQkrIUUtbVNBDcVJ9nmnO85Nj61Fsmk6PUbfm3irg_H6sDP4jV6HrRaqLqXkJPBlJ9D48IzAYYcmqJd16mWdGriGikROH1zE8GfGNOneJ4sdTQLDnHQtC6gX54T8-B_yJsxxoBFpRcGBoi2ePu1Aa9Oh9oML9Ge7SOoLUUKxqlStCHX2BIquFntvaaPOU_2AcL4j2BhSiuj2KZcUdIifyPXh8XT3-H-ntvgL1Evwfw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902216270</pqid></control><display><type>article</type><title>The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland</title><source>BioMed Central</source><source>SpringerOpen</source><source>MEDLINE</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Timonen, Johanna ; Bengtström, Marina ; Karttunen, Pekka ; Ahonen, Riitta</creator><creatorcontrib>Timonen, Johanna ; Bengtström, Marina ; Karttunen, Pekka ; Ahonen, Riitta</creatorcontrib><description>Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical companies' perspective was explored with a focus on the number of employees, the range of sales packages on the market, the marketing activities, the research and development of new pharmaceutical products and storage of pharmaceuticals.
A cross-sectional postal survey was conducted among pharmaceutical companies with an office in Finland and substitutable medicines in the Finnish pharmaceutical market one year (2004) and five years (2008) after the introduction of GS. Completed questionnaires were returned by 16 original and 7 generic product companies in 2004 (response rate 56%, n = 41) and by 16 original and 6 generic product companies in 2008 (response rate 56%, n = 39). Descriptive statistical analyses were performed.
The number of employees (2004: n = 6/16, 2008: n = 7/16) and the amount of prescription medicine marketing (2004: n = 7/16, 2008: n = 8/16) decreased in many of the original product companies after the introduction of GS. GS resulted in problems related to the storage of pharmaceuticals in the original product companies shortly after GS was introduced (p = 0.032 between 2004 and 2008). In the generic product companies, the prescription medicine representatives' visits to pharmacies increased at the beginning of GS (p = 0.021 between 2004 and 2008). In addition, GS caused problems with the storage of pharmaceuticals one year and five years after the reform (2004: n = 4/7, 2008: n = 3/6). The differences between original and generic product companies regarding the impacts of GS were not, however, statistically significant. GS did not affect on the range of sales packages on the market or the research activities of the majority of companies.
The study suggests that GS has had impacts on the activities of pharmaceutical companies in Finland. There were also some differences, although not statistically significant, between the surveyed original and generic product companies regarding the self-reported impacts of GS. More investigations are needed in this field.</description><identifier>ISSN: 1472-6904</identifier><identifier>EISSN: 1472-6904</identifier><identifier>DOI: 10.1186/1472-6904-10-15</identifier><identifier>PMID: 20964869</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Commerce - statistics & numerical data ; Competition ; Cross-Sectional Studies ; Drug Costs ; Drug Industry - statistics & numerical data ; Drug Prescriptions - statistics & numerical data ; Drug stores ; Drug Substitution - psychology ; Drugs, Generic - economics ; Drugs, Generic - therapeutic use ; Finland ; Generic drugs ; Generic products ; Health aspects ; Health sciences ; Humans ; Marketing - statistics & numerical data ; Medical care, Cost of ; Medicine ; Pharmaceutical industry ; Pharmacies ; Prospective Studies ; Reference books ; Sales ; Society ; Studies ; Surveys ; Surveys and Questionnaires ; Workload</subject><ispartof>BMC clinical pharmacology, 2010-10, Vol.10 (1), p.15-15, Article 15</ispartof><rights>COPYRIGHT 2010 BioMed Central Ltd.</rights><rights>2010 Timonen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2010 Timonen et al; licensee BioMed Central Ltd. 2010 Timonen et al; licensee BioMed Central Ltd.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4605-2150f1c522ba065fcd4b022f3d002e1693f57991c13dafa14941826276cb51713</citedby><cites>FETCH-LOGICAL-b4605-2150f1c522ba065fcd4b022f3d002e1693f57991c13dafa14941826276cb51713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974660/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974660/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,24792,27915,27916,53782,53784,75499,75500</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20964869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Timonen, Johanna</creatorcontrib><creatorcontrib>Bengtström, Marina</creatorcontrib><creatorcontrib>Karttunen, Pekka</creatorcontrib><creatorcontrib>Ahonen, Riitta</creatorcontrib><title>The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland</title><title>BMC clinical pharmacology</title><addtitle>BMC Clin Pharmacol</addtitle><description>Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical companies' perspective was explored with a focus on the number of employees, the range of sales packages on the market, the marketing activities, the research and development of new pharmaceutical products and storage of pharmaceuticals.
A cross-sectional postal survey was conducted among pharmaceutical companies with an office in Finland and substitutable medicines in the Finnish pharmaceutical market one year (2004) and five years (2008) after the introduction of GS. Completed questionnaires were returned by 16 original and 7 generic product companies in 2004 (response rate 56%, n = 41) and by 16 original and 6 generic product companies in 2008 (response rate 56%, n = 39). Descriptive statistical analyses were performed.
The number of employees (2004: n = 6/16, 2008: n = 7/16) and the amount of prescription medicine marketing (2004: n = 7/16, 2008: n = 8/16) decreased in many of the original product companies after the introduction of GS. GS resulted in problems related to the storage of pharmaceuticals in the original product companies shortly after GS was introduced (p = 0.032 between 2004 and 2008). In the generic product companies, the prescription medicine representatives' visits to pharmacies increased at the beginning of GS (p = 0.021 between 2004 and 2008). In addition, GS caused problems with the storage of pharmaceuticals one year and five years after the reform (2004: n = 4/7, 2008: n = 3/6). The differences between original and generic product companies regarding the impacts of GS were not, however, statistically significant. GS did not affect on the range of sales packages on the market or the research activities of the majority of companies.
The study suggests that GS has had impacts on the activities of pharmaceutical companies in Finland. There were also some differences, although not statistically significant, between the surveyed original and generic product companies regarding the self-reported impacts of GS. More investigations are needed in this field.</description><subject>Commerce - statistics & numerical data</subject><subject>Competition</subject><subject>Cross-Sectional Studies</subject><subject>Drug Costs</subject><subject>Drug Industry - statistics & numerical data</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Drug stores</subject><subject>Drug Substitution - psychology</subject><subject>Drugs, Generic - economics</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Finland</subject><subject>Generic drugs</subject><subject>Generic products</subject><subject>Health aspects</subject><subject>Health sciences</subject><subject>Humans</subject><subject>Marketing - statistics & numerical data</subject><subject>Medical care, Cost of</subject><subject>Medicine</subject><subject>Pharmaceutical industry</subject><subject>Pharmacies</subject><subject>Prospective Studies</subject><subject>Reference books</subject><subject>Sales</subject><subject>Society</subject><subject>Studies</subject><subject>Surveys</subject><subject>Surveys and Questionnaires</subject><subject>Workload</subject><issn>1472-6904</issn><issn>1472-6904</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1Uk1r3DAQNaWlSdOeeyuiPeTkRCPb8upSSEO_INBLehayPNpVsC1XshfyI_OfOs6mS7Yk2GB75r3n92aUZe-BnwGs5DmUtcil4mUOPIfqRXa8r7x89H6UvUnphnOoV1C8zo4EV7JcSXWc3V1vkPl-NHZiwbE1Dhi9ZWlu0uSnefJhYHRPhCKI3_rJY1qQ48bE3lgkiDUds4E0hqWXM0P0uMVb5mLo76n77ikbMaYRFykkYWS3aCIzQ8vcUlm-EjNuwnhP9MMUQzvbnY9n_PmByENHIm-zV850Cd89PE-y39--Xl_-yK9-ff95eXGVN6XkVS6g4g5sJURjuKycbcuGC-GKlnOBIFXhqlopsFC0xhkoVQkrIUUtbVNBDcVJ9nmnO85Nj61Fsmk6PUbfm3irg_H6sDP4jV6HrRaqLqXkJPBlJ9D48IzAYYcmqJd16mWdGriGikROH1zE8GfGNOneJ4sdTQLDnHQtC6gX54T8-B_yJsxxoBFpRcGBoi2ePu1Aa9Oh9oML9Ge7SOoLUUKxqlStCHX2BIquFntvaaPOU_2AcL4j2BhSiuj2KZcUdIifyPXh8XT3-H-ntvgL1Evwfw</recordid><startdate>20101022</startdate><enddate>20101022</enddate><creator>Timonen, Johanna</creator><creator>Bengtström, Marina</creator><creator>Karttunen, Pekka</creator><creator>Ahonen, Riitta</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K6~</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20101022</creationdate><title>The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland</title><author>Timonen, Johanna ; Bengtström, Marina ; Karttunen, Pekka ; Ahonen, Riitta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4605-2150f1c522ba065fcd4b022f3d002e1693f57991c13dafa14941826276cb51713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Commerce - statistics & numerical data</topic><topic>Competition</topic><topic>Cross-Sectional Studies</topic><topic>Drug Costs</topic><topic>Drug Industry - statistics & numerical data</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Drug stores</topic><topic>Drug Substitution - psychology</topic><topic>Drugs, Generic - economics</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Finland</topic><topic>Generic drugs</topic><topic>Generic products</topic><topic>Health aspects</topic><topic>Health sciences</topic><topic>Humans</topic><topic>Marketing - statistics & numerical data</topic><topic>Medical care, Cost of</topic><topic>Medicine</topic><topic>Pharmaceutical industry</topic><topic>Pharmacies</topic><topic>Prospective Studies</topic><topic>Reference books</topic><topic>Sales</topic><topic>Society</topic><topic>Studies</topic><topic>Surveys</topic><topic>Surveys and Questionnaires</topic><topic>Workload</topic><toplevel>online_resources</toplevel><creatorcontrib>Timonen, Johanna</creatorcontrib><creatorcontrib>Bengtström, Marina</creatorcontrib><creatorcontrib>Karttunen, Pekka</creatorcontrib><creatorcontrib>Ahonen, Riitta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Entrepreneurship Database (Proquest)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Timonen, Johanna</au><au>Bengtström, Marina</au><au>Karttunen, Pekka</au><au>Ahonen, Riitta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland</atitle><jtitle>BMC clinical pharmacology</jtitle><addtitle>BMC Clin Pharmacol</addtitle><date>2010-10-22</date><risdate>2010</risdate><volume>10</volume><issue>1</issue><spage>15</spage><epage>15</epage><pages>15-15</pages><artnum>15</artnum><issn>1472-6904</issn><eissn>1472-6904</eissn><abstract>Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical companies' perspective was explored with a focus on the number of employees, the range of sales packages on the market, the marketing activities, the research and development of new pharmaceutical products and storage of pharmaceuticals.
A cross-sectional postal survey was conducted among pharmaceutical companies with an office in Finland and substitutable medicines in the Finnish pharmaceutical market one year (2004) and five years (2008) after the introduction of GS. Completed questionnaires were returned by 16 original and 7 generic product companies in 2004 (response rate 56%, n = 41) and by 16 original and 6 generic product companies in 2008 (response rate 56%, n = 39). Descriptive statistical analyses were performed.
The number of employees (2004: n = 6/16, 2008: n = 7/16) and the amount of prescription medicine marketing (2004: n = 7/16, 2008: n = 8/16) decreased in many of the original product companies after the introduction of GS. GS resulted in problems related to the storage of pharmaceuticals in the original product companies shortly after GS was introduced (p = 0.032 between 2004 and 2008). In the generic product companies, the prescription medicine representatives' visits to pharmacies increased at the beginning of GS (p = 0.021 between 2004 and 2008). In addition, GS caused problems with the storage of pharmaceuticals one year and five years after the reform (2004: n = 4/7, 2008: n = 3/6). The differences between original and generic product companies regarding the impacts of GS were not, however, statistically significant. GS did not affect on the range of sales packages on the market or the research activities of the majority of companies.
The study suggests that GS has had impacts on the activities of pharmaceutical companies in Finland. There were also some differences, although not statistically significant, between the surveyed original and generic product companies regarding the self-reported impacts of GS. More investigations are needed in this field.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>20964869</pmid><doi>10.1186/1472-6904-10-15</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1472-6904 |
| ispartof | BMC clinical pharmacology, 2010-10, Vol.10 (1), p.15-15, Article 15 |
| issn | 1472-6904 1472-6904 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2974660 |
| source | BioMed Central; SpringerOpen; MEDLINE; PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Commerce - statistics & numerical data Competition Cross-Sectional Studies Drug Costs Drug Industry - statistics & numerical data Drug Prescriptions - statistics & numerical data Drug stores Drug Substitution - psychology Drugs, Generic - economics Drugs, Generic - therapeutic use Finland Generic drugs Generic products Health aspects Health sciences Humans Marketing - statistics & numerical data Medical care, Cost of Medicine Pharmaceutical industry Pharmacies Prospective Studies Reference books Sales Society Studies Surveys Surveys and Questionnaires Workload |
| title | The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T20%3A21%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20generic%20substitution%20on%20the%20activities%20of%20pharmaceutical%20companies%20-%20a%20survey%20from%20the%20companies'%20perspective%20one%20year%20and%20five%20years%20after%20the%20introduction%20of%20generic%20substitution%20in%20finland&rft.jtitle=BMC%20clinical%20pharmacology&rft.au=Timonen,%20Johanna&rft.date=2010-10-22&rft.volume=10&rft.issue=1&rft.spage=15&rft.epage=15&rft.pages=15-15&rft.artnum=15&rft.issn=1472-6904&rft.eissn=1472-6904&rft_id=info:doi/10.1186/1472-6904-10-15&rft_dat=%3Cgale_pubme%3EA241385979%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=902216270&rft_id=info:pmid/20964869&rft_galeid=A241385979&rfr_iscdi=true |